Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:budesonide
|
| gptkbp:approvalYear |
2013
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A07EA06
|
| gptkbp:brand |
gptkb:budesonide
|
| gptkbp:contraindication |
hypersensitivity to budesonide
systemic fungal infections |
| gptkbp:eliminatedIn |
urine
feces |
| gptkbp:form |
extended-release tablet
|
| gptkbp:halfLife |
2-3.6 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Uceris
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Salix_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
glucocorticoid receptor agonist
|
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
abdominal pain fatigue headache hypertension |
| gptkbp:usedFor |
ulcerative colitis
|
| gptkbp:bfsParent |
gptkb:Valeant_Pharmaceuticals_International
|
| gptkbp:bfsLayer |
7
|